MedTrace Logo

Safety Study of X-82 in Patients With Advanced Solid Tumors

NCT01296581 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2022-02-28

No results posted yet for this study

Summary

The purpose of this study is to determine the maximum tolerated dose (MTD) of X-82 as a single agent.

Conditions

Interventions

DRUG

X-82

Dose escalation starting at 20 mg, oral once or twice a day, 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.

Sponsors & Collaborators

  • Tyrogenex

    lead INDUSTRY

Principal Investigators

  • Gina Courtney, MD · Study PI

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-02-28
Primary Completion
2014-01-31
Completion
2017-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01296581 on ClinicalTrials.gov